iShares Nasdaq Biotechnology ETF (IBB)

135.20 +0.33  +0.24% NASDAQ Aug 11, 09:25 USD
View Full Chart
Price Chart

Key Stats

Net Asset Value 134.76
Discount or Premium to NAV 0.08%
Turnover Ratio 29.00%
1 Year Fund Level Flows 798.18M

Performance & Returns

  Total Return (Price) Total Return (NAV) Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M -3.12% -3.20% 2.90% 92
3M 5.13% 5.04% 11.00% 87
6M 10.06% 9.97% 8.56% 20
YTD 12.09% 11.95% 9.88% 24
1Y 28.21% 28.18% 25.56% 18
3Y 10.19% 10.16% 12.59% 82
5Y 1.94% 1.92% 7.27% 91
10Y 17.26% 17.27% 15.92% 30
15Y 12.16% 12.16% 11.18% 31
20Y -- -- 9.02% --
As of Aug. 10, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 0.12% 0.12% 0.00%
Stock 99.88% 99.88% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Aug. 7, 2020

Region Exposure

Americas 91.97%
North America 91.97%
Latin America 0.00%
Greater Europe 5.22%
United Kingdom 1.39%
Europe Developed 3.70%
Europe Emerging 0.00%
Africa/Middle East 0.13%
Greater Asia 2.81%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.20%
Asia Emerging 2.61%
Market Classification
% Developed Markets 97.39%
% Emerging Markets 2.61%
As of Aug. 7, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.08%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 99.92%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Aug. 7, 2020

Stock Market Capitalization

Giant 9.45%
Large 38.93%
Medium 29.50%
Small 19.07%
Micro 3.05%
As of Aug. 7, 2020

Stock Style Exposure

Large Cap Value 21.94%
Large Cap Blend 0.27%
Large Cap Growth 28.62%
Mid Cap Value 2.34%
Mid Cap Blend 5.81%
Mid Cap Growth 22.08%
Small Cap Value 1.37%
Small Cap Blend 4.76%
Small Cap Growth 12.80%
As of Aug. 7, 2020
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
AMGN Amgen Inc 8.23% 238.60 +0.18%
VRTX Vertex Pharmaceuticals Inc 7.38% 266.09 -0.98%
GILD Gilead Sciences Inc 7.00% 68.50 -0.01%
REGN Regeneron Pharmaceuticals Inc 6.52% 606.45 -0.29%
ILMN Illumina Inc 5.45% 353.30 -0.01%
BIIB Biogen Inc 3.91% 302.27 +0.67%
MRNA Moderna Inc 3.07% 69.80 -3.07%
SGEN Seattle Genetics Inc 2.96% 158.00 +0.19%
ALXN Alexion Pharmaceuticals Inc 2.43% 101.89 +0.01%
BMRN Biomarin Pharmaceutical Inc 2.29% 118.25 -0.35%
As of Aug. 7, 2020
Advertisement

Basic Info

Investment Strategy
The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Technology
Fund Owner Firm Name iShares
Benchmark Index
NASDAQ Biotechnology TR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Alan Mason 4.30 yrs
Amy Whitelaw 2.00 yrs
Greg Savage 12.59 yrs
Jennifer Hsui 8.01 yrs
Rachel Aguirre 2.00 yrs

Net Fund Flows

1M 372.17M
3M 1.141B
6M 1.405B
YTD 1.464B
1Y 798.18M
3Y -1.705B
5Y -639.68M
10Y 2.363B
As of July 31, 2020

Risk Info

Beta (5Y) 1.178
Max Drawdown (All) 62.85%
Historical Sharpe Ratio (10Y) 0.8858
Historical Sortino (All) 0.5526
30-Day Rolling Volatility 22.62%
Daily Value at Risk (VaR) 1% (All) 4.83%
Monthly Value at Risk (VaR) 1% (All) 19.37%

Fundamentals

Dividend Yield TTM (8-11-20) 0.23%
30-Day SEC Yield (3-31-20) 0.30%
7-Day SEC Yield --
Weighted Average PE Ratio 23.55
Weighted Average Price to Sales Ratio 6.836
Weighted Average Price to Book Ratio 5.532
Weighted Median ROE 1.96%
Weighted Median ROA -6.55%
Forecasted Dividend Yield 0.60%
Forecasted PE Ratio 16.50
Forecasted Price to Sales Ratio 5.498
Forecasted Price to Book Ratio 4.735
Number of Holdings 212
As of Aug. 7, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth 9.03%
Forecasted Book Value Growth 6.05%
Forecasted Cash Flow Growth 7.28%
Forecasted Earnings Growth 14.11%
Forecasted Revenue Growth 7.51%
As of Aug. 7, 2020

Comparables

Edit

Attributes

Key Dates
Inception Date 2/5/2001
Termination Date
Last Annual Report Date 3/31/2020
Last Prospectus Date 7/31/2020
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.